Literature DB >> 11063507

Evaluation of antibodies against a rubella virus neutralizing domain for determination of immune status.

P Cordoba1, A Lanoel, S Grutadauria, M Zapata.   

Abstract

The protective immune responses against rubella virus (RV) are related to its neutralizing epitopes, an issue that is important to consider when assessing the immune status of patients with remote infection. In the present paper, we compare the antibodies detected by a synthetic-peptide-based enzyme immunoassay (EIA) with antibodies detected by the traditional technique of hemagglutination inhibition (HIA) in patients with remote RV infection. The synthetic peptide used as an antigen (SP15) represents a neutralizing epitope that corresponds to amino acids 208 to 239 of the E1 glycoprotein. The SP15-EIA was developed, all variables that affected the assay were standardized, and the test was validated using reference sera. Serum samples (n = 129) from patients with remote RV infection were tested by HIA and SP15-EIA. Discrepant sera were assayed by MEIA (IMX/Abbot). The comparison between HIA and SP15-EIA, taking HIA as the standard methodology for determining immune status, showed that SP15-EIA is very specific and sensitive for detecting protecting antibodies (specificity, 100%; sensitivity, 98.20%). This study demonstrates that antibodies against the neutralizing domain represented by SP15 would be important in the memory response after natural infection and may be a good tool in the determination of the true immune status of patients with remote infection with regard to RV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063507      PMCID: PMC95994          DOI: 10.1128/CDLI.7.6.964-966.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  23 in total

1.  Structure of rubella E1 glycoprotein epitopes established by multiple peptide synthesis.

Authors:  L Lozzi; M Rustici; M Corti; M G Cusi; P E Valensin; L Bracci; A Santucci; P Soldani; A Spreafico; P Neri
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Rubella virus antigens: localization of epitopes involved in hemagglutination and neutralization by using monoclonal antibodies.

Authors:  K Y Green; P H Dorsett
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

3.  Serological evidence of reinfection among vaccinees during rubella outbreak.

Authors:  M G Cusi; G M Rossolini; P E Valensin; C Cellesi; A Zanchi
Journal:  Lancet       Date:  1990-10-27       Impact factor: 79.321

4.  Presence of a neutralizing domain in isolates of rubella virus in Cordoba, Argentina.

Authors:  P Cordoba; S L Grutadauria; C Cuffini; M T Zapata
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

5.  Comparison of immune response to rubella virus proteins in early and late natural infections.

Authors:  S V Nates; S E Mersich; E B Damonte; M T Zapata
Journal:  Microbiologica       Date:  1989-10

6.  Rubella reinfection; role of neutralising antibodies and cell-mediated immunity.

Authors:  S O'Shea; K M Corbett; S M Barrow; J E Banatvala; J M Best
Journal:  Clin Diagn Virol       Date:  1994-10

7.  Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay.

Authors:  L A Mitchell; T Zhang; M Ho; D Décarie; A J Tingle; M Zrein; M Lacroix
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

8.  Rubella virus contains one capsid protein and three envelope glycoproteins, E1, E2a, and E2b.

Authors:  C Oker-Blom; N Kalkkinen; L Kääriäinen; R F Pettersson
Journal:  J Virol       Date:  1983-06       Impact factor: 5.103

9.  Comparison of a whole-virus enzyme immunoassay (EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G antibodies following rubella vaccination.

Authors:  M Zrein; J H Joncas; L Pedneault; L Robillard; R J Dwyer; M Lacroix
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

10.  An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain.

Authors:  J S Wolinsky; E Sukholutsky; W T Moore; A Lovett; M McCarthy; B Adame
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  4 in total

Review 1.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

2.  Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].

Authors:  Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

Review 3.  Rubella.

Authors:  Nathaniel Lambert; Peter Strebel; Walter Orenstein; Joseph Icenogle; Gregory A Poland
Journal:  Lancet       Date:  2015-01-08       Impact factor: 79.321

4.  Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Authors:  Iana H Haralambieva; Michael J Gibson; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.